vs
AtriCure, Inc.（ATRC）与弗雷斯特研究公司（FORR）财务数据对比。点击上方公司名可切换其他公司
AtriCure, Inc.的季度营收约是弗雷斯特研究公司的1.4倍（$140.5M vs $101.1M），AtriCure, Inc.同比增速更快（13.1% vs -6.5%），AtriCure, Inc.自由现金流更多（$18.4M vs $-4.3M），过去两年AtriCure, Inc.的营收复合增速更高（13.6% vs 0.5%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
ATRC vs FORR — 直观对比
营收规模更大
ATRC
是对方的1.4倍
$101.1M
营收增速更快
ATRC
高出19.5%
-6.5%
自由现金流更多
ATRC
多$22.7M
$-4.3M
两年增速更快
ATRC
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.5M | $101.1M |
| 净利润 | — | $-33.9M |
| 毛利率 | 75.0% | 56.7% |
| 营业利润率 | 1.8% | -36.6% |
| 净利率 | — | -33.5% |
| 营收同比 | 13.1% | -6.5% |
| 净利润同比 | — | -7941.4% |
| 每股收益（稀释后） | $0.04 | $-1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCFORR
| Q4 25 | $140.5M | $101.1M | ||
| Q3 25 | $134.3M | $94.3M | ||
| Q2 25 | $136.1M | $111.7M | ||
| Q1 25 | $123.6M | $89.9M | ||
| Q4 24 | $124.3M | $108.0M | ||
| Q3 24 | $115.9M | $102.5M | ||
| Q2 24 | $116.3M | $121.8M | ||
| Q1 24 | $108.9M | $100.1M |
净利润ATRCFORR
| Q4 25 | — | $-33.9M | ||
| Q3 25 | $-267.0K | $-2.1M | ||
| Q2 25 | $-6.2M | $3.9M | ||
| Q1 25 | $-6.7M | $-87.3M | ||
| Q4 24 | — | $432.0K | ||
| Q3 24 | $-7.9M | $-5.8M | ||
| Q2 24 | $-8.0M | $6.3M | ||
| Q1 24 | $-13.3M | $-6.7M |
毛利率ATRCFORR
| Q4 25 | 75.0% | 56.7% | ||
| Q3 25 | 75.5% | 60.0% | ||
| Q2 25 | 74.5% | 55.5% | ||
| Q1 25 | 74.9% | 55.9% | ||
| Q4 24 | 74.5% | 58.8% | ||
| Q3 24 | 74.9% | 60.5% | ||
| Q2 24 | 74.7% | 57.3% | ||
| Q1 24 | 74.7% | 54.9% |
营业利润率ATRCFORR
| Q4 25 | 1.8% | -36.6% | ||
| Q3 25 | 0.2% | 4.7% | ||
| Q2 25 | -4.5% | 6.2% | ||
| Q1 25 | -4.8% | -97.5% | ||
| Q4 24 | -11.7% | -0.5% | ||
| Q3 24 | -6.4% | -0.7% | ||
| Q2 24 | -6.2% | 9.3% | ||
| Q1 24 | -10.0% | -9.3% |
净利率ATRCFORR
| Q4 25 | — | -33.5% | ||
| Q3 25 | -0.2% | -2.3% | ||
| Q2 25 | -4.5% | 3.5% | ||
| Q1 25 | -5.5% | -97.1% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | -6.8% | -5.7% | ||
| Q2 24 | -6.9% | 5.2% | ||
| Q1 24 | -12.2% | -6.7% |
每股收益（稀释后）ATRCFORR
| Q4 25 | $0.04 | $-1.75 | ||
| Q3 25 | $-0.01 | $-0.11 | ||
| Q2 25 | $-0.13 | $0.20 | ||
| Q1 25 | $-0.14 | $-4.62 | ||
| Q4 24 | $-0.33 | $0.02 | ||
| Q3 24 | $-0.17 | $-0.30 | ||
| Q2 24 | $-0.17 | $0.33 | ||
| Q1 24 | $-0.28 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.4M | $63.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $491.9M | $126.5M |
| 总资产 | $654.2M | $404.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCFORR
| Q4 25 | $167.4M | $63.3M | ||
| Q3 25 | $147.9M | $65.1M | ||
| Q2 25 | $117.8M | $67.8M | ||
| Q1 25 | $99.9M | $75.6M | ||
| Q4 24 | $122.7M | $56.1M | ||
| Q3 24 | $130.3M | $62.8M | ||
| Q2 24 | $114.0M | $58.9M | ||
| Q1 24 | $106.0M | $61.4M |
总债务ATRCFORR
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — | ||
| Q1 24 | $61.9M | — |
股东权益ATRCFORR
| Q4 25 | $491.9M | $126.5M | ||
| Q3 25 | $476.5M | $157.7M | ||
| Q2 25 | $464.5M | $159.5M | ||
| Q1 25 | $454.6M | $147.4M | ||
| Q4 24 | $461.0M | $229.5M | ||
| Q3 24 | $465.0M | $234.3M | ||
| Q2 24 | $462.1M | $237.1M | ||
| Q1 24 | $456.3M | $230.9M |
总资产ATRCFORR
| Q4 25 | $654.2M | $404.0M | ||
| Q3 25 | $635.4M | $414.2M | ||
| Q2 25 | $608.8M | $436.0M | ||
| Q1 25 | $591.6M | $439.8M | ||
| Q4 24 | $609.3M | $503.9M | ||
| Q3 24 | $615.1M | $505.3M | ||
| Q2 24 | $597.3M | $524.2M | ||
| Q1 24 | $591.6M | $555.7M |
负债/权益比ATRCFORR
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | $18.4M | $-4.3M |
| 自由现金流率自由现金流/营收 | 13.1% | -4.2% |
| 资本支出强度资本支出/营收 | 1.1% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $48.3M | $18.1M |
8季度趋势，按日历期对齐
经营现金流ATRCFORR
| Q4 25 | $20.0M | $-3.2M | ||
| Q3 25 | $26.7M | $1.2M | ||
| Q2 25 | $21.6M | $-3.6M | ||
| Q1 25 | $-11.0M | $26.7M | ||
| Q4 24 | $5.8M | $-1.8M | ||
| Q3 24 | $20.0M | $264.0K | ||
| Q2 24 | $7.4M | $-2.9M | ||
| Q1 24 | $-21.0M | $611.0K |
自由现金流ATRCFORR
| Q4 25 | $18.4M | $-4.3M | ||
| Q3 25 | $24.1M | $524.0K | ||
| Q2 25 | $19.0M | $-4.2M | ||
| Q1 25 | $-13.2M | $26.1M | ||
| Q4 24 | $3.1M | $-2.5M | ||
| Q3 24 | $16.4M | $-223.0K | ||
| Q2 24 | $5.0M | $-3.7M | ||
| Q1 24 | $-23.8M | $-815.0K |
自由现金流率ATRCFORR
| Q4 25 | 13.1% | -4.2% | ||
| Q3 25 | 18.0% | 0.6% | ||
| Q2 25 | 13.9% | -3.8% | ||
| Q1 25 | -10.7% | 29.0% | ||
| Q4 24 | 2.5% | -2.3% | ||
| Q3 24 | 14.1% | -0.2% | ||
| Q2 24 | 4.3% | -3.1% | ||
| Q1 24 | -21.9% | -0.8% |
资本支出强度ATRCFORR
| Q4 25 | 1.1% | 1.1% | ||
| Q3 25 | 1.9% | 0.7% | ||
| Q2 25 | 2.0% | 0.5% | ||
| Q1 25 | 1.8% | 0.7% | ||
| Q4 24 | 2.2% | 0.6% | ||
| Q3 24 | 3.1% | 0.5% | ||
| Q2 24 | 2.1% | 0.7% | ||
| Q1 24 | 2.5% | 1.4% |
现金转化率ATRCFORR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4.24× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.46× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
